Australia's best minds in melanoma research converge on Melbourne
8 October 2018
The 2018 Australasian Melanoma Conference, held in Melbourne over the weekend, focussed on the integration of research and clinical care.
Melanoma Institute Australia’s Medical Directors, Professor Georgina Long and Professor Richard Scolyer, led the large contingent from MIA. In the targeted therapies session, Professor Long asked “where to next?”, while Professor Scolyer spoke on the challenges associated with borderline lesions and, in the Saturday lunchtime plenary session, discussed predicting patient outcomes.
Among the team of MIA clinicians was Professor Graham Mann who presented insights from the Australian Melanoma Genome Project and the Australian Melanoma Clinical Outcomes Registry. Associate Professor Pascale Guitera spoke on dermoscopy and provided an educational course on confocal microscopy, and Associate Professor Jon Stretch, Professor Angela Hong, Professor Peter Hersey and research affiliates Professor Nick Hayward and Professor Helen Rizos all chaired sessions.
A joint presentation from Professor Andrew Spillane and Associate Professor Alex Menzies in the management of loco-regional disease session provided both surgical and medical approaches to regional disease. Professor Diona Damian debated topical and injectable therapies for cutaneous melanoma, and Associate Professor Robyn Saw discussed follow-up and investigation for high-risk melanoma patients in the supportive care and survivorship session. A clinician’s perspective of The National Melanoma Guidelines from Professor John Thompson rounded out the weekend.
A highlight of the conference was the Consumer Breakfast, where a panel of people affected by melanoma, including MIA’s Jay Allen, discussed solariums, early detection, and the importance of support and routines after diagnosis. They shared stories, hope, and the importance of fundraising. “We need to keep raising funds, by organising events in local areas or supporting larger fundraising campaigns, because without funding, we don’t have research,” Mr Allen said.
Photograph: Australasian Melanoma Conference
Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Sharing our knowledge of melanoma on the global stage
As leaders in the field of melanoma, clinicians and researchers from MIA will be sharing their knowledge at the virtual 10th World Congress of Melanoma.
Community Fundraising Wrap Up Jan-Mar 2021
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
Support for Melanoma March has come from everywhere
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
An inspiring WA Melanoma Community Forum
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
Family of 8-year-old with melanoma calls on all Australians to step up to help save lives
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
Rethinking skin surveillance for high-risk melanoma patients
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Australia's oldest melanoma survivor steps up to save lives on his 105th birthday
Melanoma research saved Bert's life at 101 and now he wants to give back.
Predicting disease spread in thin melanoma
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.
Exploring our own clinical questions through MIA's new trials initiative
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Young researchers receive boost to develop innovative treatment for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Launch of Melanoma March 2021
Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.
Olivia Vivian announced as MIA ambassador
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.
Melanoma breakthrough - neoadjuvant treatment saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Melanoma breakthrough - neoadjuvant therapy saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.